A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002
A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Source: Eur Respir J 2013; 41: 12-17 Year: 2013
Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 639-644 Year: 2002
Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis Source: Annual Congress 2013 –COPD diagnosis Year: 2013
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008